Unlocking Health Insights

Lifebit, a Scale Up Cohort 1 alumnus, is enhancing healthcare by enabling secure, scalable access to distributed clinical and multi-omic data. With 97% of life-saving health data being fragmented and inaccessible, Lifebit’s platform brings analysis directly to where the data resides, accelerating drug discovery, personalized medicine, and disease research.

Equipped with AI-powered data standardization and automated analytics, Lifebit helps pharmaceutical companies and healthcare providers overcome challenges in identifying drug targets and speeding up drug development. The platform also addresses global health threats like cancer, cardiovascular diseases, and neurological disorders.

By democratizing access to complex omics data, Lifebit empowers researchers of all levels to run fast, meaningful analyses. Trusted by leading biomedical organizations like Genomics England and the University of Cambridge, Lifebit is revolutionizing how research is conducted. In 2024, Lifebit expanded its accessibility by launching on the Amazon Web Services (AWS) Marketplace, making its platform available to health and research organizations worldwide, further accelerating progress in precision medicine.

Lifebit in Three:

• What problem is Lifebit solving? Lifebit is solving the challenge of securely managing and analyzing genomic data without exposing individuals’ sensitive genetic information.

• What's innovative about Lifebit? Lifebit’s innovation lies in its advanced, AI-powered platform that acts as a secure vault, enabling researchers to explore genomic data for precision medicine without compromising data privacy.

• Who can use Lifebit? Pharmaceutical companies, research institutes, and genetics firms looking to securely harness genomic data for medical research and discoveries can use Lifebit.

The company is a graduate of TechStars accelerator and works with top-tier pharmaceutical organizations, global research institutes, genetics companies, and other institutions globally, including the likes of Genomics England and Boehringer Ingelheim. In 2021 the company secured funding of $60 million, from a top-tier fund, Tiger Global. In February of 2023, Lifebit announced its part in the BeginNGS project, a genome sequencing program supported by Greece’s National Organization of Public Health. The initiative will enable the sequencing of genomes of 1,000 newborns in its first year for the early detection of rare diseases, aiming to expand the sequencing to all newborns in Greece until 2027.